Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Nicholas Trudo

Physician Assistant Joint Base Charleston, SC Physician Assistant

NPI 1467938290 CMS profile 11410225

204 W Hill Blvd, Joint Base Charleston, SC 29404

Open in the dashboard

General payments

$6,750

286 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Trudo of Joint Base Charleston, SC is reported in the CMS Open Payments database as having received $6,750 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,563 140
2024 General $3,065 140
2023 General $122 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Trudo
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nicholas Trudo were reported at $3,563. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nicholas Trudo Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $122 $167 $52–$557 $160
2024 $3,065 $178 $55–$600 $164
2025 $3,563 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Insulet Corporation $614 19 payments
  2. Lilly USA, LLC $566 25 payments
  3. Amgen Inc. $550 27 payments
  4. Novo Nordisk Inc $530 27 payments
  5. Sanofi-Aventis U.S. LLC $521 14 payments
  6. Xeris Pharmaceuticals, Inc. $466 25 payments
  7. Corcept Therapeutics $377 28 payments
  8. Beta Bionics, Inc. $309 11 payments
  9. Dexcom, Inc. $304 5 payments
  10. CeQur Corporation $246 2 payments
  11. Other $2,267 103 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $6,750 286 payments
Products named General payments · program years 2023–2025
  1. Omnipod $614 19 payments
  2. TZIELD $496 13 payments
  3. Ozempic $422 21 payments
  4. MOUNJARO $422 18 payments
  5. TEPEZZA $412 18 payments
  6. Korlym $377 28 payments
  7. RECORLEV $334 17 payments
  8. ZEPBOUND $260 11 payments
  9. CeQur Simplicity $246 2 payments
  10. iLet Insulin Infusion Kit Inset $235 7 payments
  11. Other $4,561 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,022

Median for Physician Assistant: 241

Drug cost

$468,787

Median for Physician Assistant: $4,110

Branded share of claims

49.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 110 $152,713
Jardiance Empagliflozin Brand 69 $97,026
Ozempic Semaglutide Brand 54 $71,286
Farxiga Dapagliflozin Propanediol Brand 56 $53,047
Trulicity Dulaglutide Brand 19 $22,520
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $19,889
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 11 $16,020
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $8,916
Nexlizet Bempedoic Acid/Ezetimibe Brand 12 $4,704
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 21 $4,487

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
  • Amgen Inc. $332
$332 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $301
$301 — —
MOUNJARO
  • Lilly USA, LLC $225
$225 110 —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $195
$195 — —
Korlym
  • Corcept Therapeutics $189
$189 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record